Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of JPI-547 in platinum-resistant advanced or relapsed ovarian cancer patients previously treated with a PARP in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• JPI-547

Snippet

Sponsor: Onconic Therapeutics Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING